NCT06997068 2026-04-17
Methotrexate, Erlotinib, and Celecoxib for the Treatment of Recurrent/Metastatic Oral Cavity Cancer in a Rural Midwest United States Population
Mayo Clinic
Phase 2 Recruiting
Mayo Clinic
National Cancer Institute (NCI)
Canadian Cancer Trials Group
OBI Pharma, Inc
Rigshospitalet, Denmark
Hunan Province Tumor Hospital
The Netherlands Cancer Institute